Investor Relations

About AVROBIO

 

Our vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal to durably express the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.

 

Sign up for email alerts

Stock Chart


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events & Presentations

Our News Latest press releases

Nov 17, 2022

AVROBIO to Share Comprehensive Gaucher Disease Program Update

Webcast on Wednesday, Dec. 7, 2022, at 8 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 17, 2022-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease

Read More

Nov 08, 2022

AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update

Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis Rare pediatric disease designations received for Gaucher disease and cystinosis investigational gene therapies Comprehensive Gaucher disease program update planned for Wednesday, Dec. 7 CAMBRIDGE, Mass.

Read More

Nov 07, 2022

AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2022-- AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced senior management will be participating in a virtual panel titled “Genomic Medicines – Evolving

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.